Evidence map›Paper›PMID 39131151›Full record

ArticleGastro hep advances2024

Investigating iRHOM2-Associated Transcriptional Changes in Tylosis With Esophageal Cancer.

Stephen Murtough, Deepak Babu, Catherine M Webb, Hélène Louis Dit Picard, Lisa A McGinty, Jennifer Chao-Chu, Ryan Pink, Andrew R Silver, Howard L Smart, John K Field and 5 more

Abstract read
In one paragraph

Article in Gastro hep advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Stephen MurtoughFaculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
Deepak BabuFaculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
Catherine M WebbFaculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
Hélène Louis Dit PicardFaculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
Lisa A McGintyFaculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
Jennifer Chao-ChuFaculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
Ryan PinkDepartment of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK.
Andrew R SilverFaculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
Howard L SmartGastroenterology and Liver Services, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
John K FieldDepartment of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Philip WoodlandEndoscopy Unit, Barts Health NHS Trust, The Royal London Hospital, London, UK.
Janet M RiskDepartment of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Diana C BlaydonFaculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
Daniel J PenningtonFaculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
David P KelsellFaculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.

Funding

Cancer Research UK 19107Medical Research Council MR/S009914/1
6 · The paper itself

Abstract

Background and Aims: Survival rates for esophageal squamous cell carcinoma (ESCC) are extremely low due to the late diagnosis of most cases. An understanding of the early molecular processes that lead to ESCC may facilitate opportunities for early diagnosis; however, these remain poorly defined. Tylosis with esophageal cancer (TOC) is a rare syndrome associated with a high lifetime risk of ESCC and germline mutations in Methods: Esophageal biopsies were obtained from control and TOC individuals, the latter undergoing surveillance endoscopy, and adjacent diagnostic biopsies were graded as having no dysplasia or malignancy. Bulk RNA-Seq was performed, and findings were compared with sporadic ESCC vs normal RNA-Seq datasets. Results: Multiple transcriptional changes were identified in TOC samples, relative to controls, and many were detected in ESCC. Accordingly, pathway analyses predicted an enrichment of cancer-associated processes linked to cellular proliferation and metastasis, and several transcription factors were predicted to be associated with TOC and ESCC, including negative enrichment of GRHL2. Subsequently, a filtering strategy revealed 22 genes that were significantly dysregulated in both TOC and ESCC. Moreover, Keratin 17, which was upregulated in TOC and ESCC, was also found to be overexpressed at the protein level in 'normal' TOC esophagus tissue. Conclusion: Transcriptional changes occur in TOC esophagus prior to the onset of dysplasia, many of which are associated with ESCC. These findings support the utility of TOC to help reveal the early molecular processes that lead to sporadic ESCC.

Indexed as

Early Cancer DetectionESCCiRhom2RNA-SeqTylosis With Esophageal Cancer

Identifiers

PMID39131151
PMCPMC11307647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.